The Radiotherapy Software market outlook remains compelling, driven by rising cancer incidence, expanding reimbursement frameworks, and accelerating digital transformation in oncology clinics. Market attractiveness is high, with a projected CAGR above 12% through 2032, underpinned by strong demand for adaptive planning, AI‑driven dose optimization, and cloud‑based workflow solutions. Competitive intensity is moderate‑high; a handful of legacy vendors defend sizable installed bases, while nimble newcomers leverage open‑source platforms and strategic partnerships to erode market share. Long‑term outlook suggests sustained growth as personalized radiotherapy becomes standard of care, though consolidation may intensify. The innovation landscape is vibrant, highlighted by AI‑powered contouring, real‑time imaging integration, and patient‑centric tele‑monitoring, creating differentiation opportunities. Demand‑supply balance currently favors suppliers, given limited capacity for rapid software customization and the lengthy validation cycles in clinical settings. Key risk factors include regulatory delays, data‑privacy constraints, and potential reimbursement roll‑backs, which could temper adoption velocity.